Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.39 |
| ▸ | XDH | P47989 | 2/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6596273 | 0.92 | XDH (0.44) | XDHPTGDR2MCL1PTGER1 | |
| SCHEMBL6080093 | 0.87 | MMP2 (0.36) | XDHEGLN1SLC6A2SLC6A3KMT2A | |
| SCHEMBL6080213 | 0.85 | CTSL (0.44) | XDHTDP1 | |
| SCHEMBL6079919 | 0.82 | MAPT (0.41) | ADORA3XDHPTGDR2EGLN1SLC6A2 | |
| SCHEMBL6079894 | 0.82 | THRA (0.42) | EGLN1SLC6A2SLC6A3KMT2ATDP1 | |
| SCHEMBL6080642 | 0.81 | P2RY14 (0.42) | MCL1SLC6A2SLC6A3KMT2ATDP1 | |
| SCHEMBL6594101 | 0.80 | MCL1 (0.43) | XDHMCL1PTGER1 | |
| SCHEMBL6079838 | 0.80 | MMP2 (0.31) | — | |
| SCHEMBL6598552 | 0.79 | XDH (0.42) | XDHMCL1PTGER1 | |
| SCHEMBL6079765 | 0.79 | NOTUM (0.41) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | claimed |
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NQO1, NQO2, RECQL | ADORA3 1328/4885XDH 128/4885PTGDR2 3561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.